Mathieu F. Crupi

Ottawa, ON, Canada

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 34 publications

Oncolytic vaccinia virus encoding constitutively active EPAC remodels the tumor microenvironment to enhance therapeutic efficacy with chemotherapy and surgery.

Oncolytic vaccinia virus encoding constitutively active EPAC remodels the tumor microenvironment to enhance therapeutic efficacy with chemotherapy and surgery.

Journal: Journal for immunotherapy of cancer

Published: January 01, 2026

Cargo-selective regulation of clathrin-mediated endocytosis by AMP-activated protein kinase.

Cargo-selective regulation of clathrin-mediated endocytosis by AMP-activated protein kinase.

Journal: iScience

Published: November 08, 2024

Loss of tumor suppressor TMEM127 drives RET-mediated transformation through disrupted membrane dynamics.

Loss of tumor suppressor TMEM127 drives RET-mediated transformation through disrupted membrane dynamics.

Journal: eLife

Published: April 30, 2024

High throughput screen identifies lysosomal acid phosphatase 2 (ACP2) to regulate IFN-1 responses to potentiate oncolytic VSV∆51 activity.

High throughput screen identifies lysosomal acid phosphatase 2 (ACP2) to regulate IFN-1 responses to potentiate oncolytic VSV∆51 activity.

Journal: Scientific reports

Published: January 16, 2024

Complementary dual-virus strategy drives synthetic target and cognate T-cell engager expression for endogenous-antigen agnostic immunotherapy.

Complementary dual-virus strategy drives synthetic target and cognate T-cell engager expression for endogenous-antigen agnostic immunotherapy.

Journal: Nature communications

Published: October 12, 2023

Loss of Tumour Suppressor TMEM127 Drives RET-mediated Transformation Through Disrupted Membrane Dynamics.

Loss of Tumour Suppressor TMEM127 Drives RET-mediated Transformation Through Disrupted Membrane Dynamics.

Journal: bioRxiv : the preprint server for biology

Published: July 10, 2023

Optimal delivery of RNA interference by viral vectors for cancer therapy.

Optimal delivery of RNA interference by viral vectors for cancer therapy.

Journal: Molecular therapy : the journal of the American Society of Gene Therapy

Published: May 31, 2023

A T cell-targeted multi-antigen vaccine generates robust cellular and humoral immunity against SARS-CoV-2 infection.

A T cell-targeted multi-antigen vaccine generates robust cellular and humoral immunity against SARS-CoV-2 infection.

Journal: Molecular therapy. Methods & clinical development

Published: May 02, 2023

Engineering Rapalog-Inducible Genetic Switches Based on Split-T7 Polymerase to Regulate Oncolytic Virus-Driven Production of Tumour-Localized IL-12 for Anti-Cancer Immunotherapy.

Engineering Rapalog-Inducible Genetic Switches Based on Split-T7 Polymerase to Regulate Oncolytic Virus-Driven Production of Tumour-Localized IL-12 for Anti-Cancer Immunotherapy.

Journal: Pharmaceuticals (Basel, Switzerland)

Published: March 20, 2023

Syngeneic mouse model of human HER2+ metastatic breast cancer for the evaluation of trastuzumab emtansine combined with oncolytic rhabdovirus.

Syngeneic mouse model of human HER2+ metastatic breast cancer for the evaluation of trastuzumab emtansine combined with oncolytic rhabdovirus.

Journal: Frontiers in immunology

Published: March 06, 2023

Inhibition of exchange proteins directly activated by cAMP as a strategy for broad-spectrum antiviral development.

Inhibition of exchange proteins directly activated by cAMP as a strategy for broad-spectrum antiviral development.

Journal: The Journal of biological chemistry

Published: February 08, 2023

Synthetic virology approaches to improve the safety and efficacy of oncolytic virus therapies.

Synthetic virology approaches to improve the safety and efficacy of oncolytic virus therapies.

Journal: Nature communications

Published: December 15, 2022

Showing 1-12 of 34

Last Updated: 09/26/2026